The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments
Open accessAbstract
Predicting tumor sensitivity to antineoplastics remains an elusive challenge, with no methods demonstrating predictive power. Joint analysis of tumors—from patients with distinct malignancies who had progressed on multiple lines of therapy—and drug perturbation transcriptional profiles predicted sensitivity to 28 of 350 drugs, 26 of which (93%) were confirmed in low-passage, patient-derived xenograft (PDX) models. Drugs were prioritized based on their ability to either invert the activity of individual Master Regulator proteins, with available high-affinity inhibitors, or of the modules they comprise (Tumor-Checkpoints), based on de novo mechanism of action analysis. Of 138 PDX mice enrolled in 16 single and 18 multi-protein treatment arms, a disease control rate (DCR) of 68% and 91 %, and an objective response rate (ORR) of 12% and 17%, were achieved respectively, compared to 6% and 0% in the negative controls arm, with multi-protein drugs achieving significantly more durable responses. Thus, these approaches may effectively complement and expand current precision oncology approaches, as also illustrated by a case study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These PDX model systems are of particular value in both basic science and potentially personalized medicine research 180,183,222 as they have clinical and molecular features that are quite representative of the human disease 223,224,225,226 .”
From Osteosarcoma (2022) · cites this paper as [226]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Cited by
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
NetBID2 provides comprehensive hidden driver analysis
Dong, X., Ding, L., Thrasher, A., Wang, X., Liu, J., Pan, Q., Rash, J., Dhungana, Y., Yang, X., Risch, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38335-6 · Cited by 37
PDX models for functional precision oncology and discovery science
Blanchard, Z., Brown, E. A., Ghazaryan, A., & Welm, A. L. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00779-3 · Cited by 69
Rosenberger, G., Li, W., Turunen, M. M., He, J., Subramaniam, P. S., Pampou, S., Griffin, A. T., Karan, C., Kerwin, P., Murray, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47957-3 · Cited by 24
Self-citationFailli, M., Demir, S., Río-Álvarez, Á. D., Carrillo-Reixach, J., Royo, L., Domingo-Sàbat, M., Childs, M., Maibach, R., Alaggio, R., Czauderna, P. S., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000601 · Cited by 16
Metadata
- Authors
- Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K. C., Siddiquee, A., You, D., Realubit, R., Karan, C., Ortiz, M. V., Accordino, M., Mistretta, S., Brogan, F., Bruce, J. N., Caescu, C. I., Carvajal, R., Crew, K., Decastro, G., Heaney, M., Henick, B., Hershman, D., Hou, J., Iwamoto, F., Jurcic, J., Kiran, R. P., Kluger, M., Kreisl, T., Lamanna, N., Lassman, A., Lim, E., Manji, G. A., McKhann, G., McKiernan, J., Neugut, A., Olive, K., Rosenblat, T., Schwartz, G. K., Shu, C., Sisti, M., Tergas, A., Vattakalam, R., Welch, M., Wenske, S., Wright, J. D., Hibshoosh, H., Kalinsky, K., Aburi, M., Sims, P. A., Alvarez, M. J., Kung, A. L., & Califano, A.
- Affiliations
- Columbia University Irving Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Emory University (US)
- Corresponding author
- Alvarez, Mariano J.
- Kung, Andrew L.
- Califano, Andrea
- ORCID
- Mundi, Prabhjot S.
- Dela Cruz, Filemon S.
- Grunn, Adina
- Diolaiti, Daniel
- Mauguen, Audrey
- Rainey, Allison R.
- Guillan, Kristina C.
- Siddiquee, Armaan
- You, Daoqi
- Realubit, Ronald
- Karan, Charles
- Ortiz, Michael V.
- Accordino, Melissa
- Mistretta, Suzanne
- Brogan, Frances
- Bruce, Jeffrey N.
- Caescu, Cristina I.
- Carvajal, Richard
- Crew, Katherine
- Decastro, Guarionex
- Heaney, Mark
- Henick, Brian
- Hershman, Dawn
- Hou, June
- Iwamoto, Fabio
- Jurcic, Joseph
- Kiran, Ravi P.
- Kluger, Michael
- Kreisl, Teri
- Lamanna, Nicole
- Lassman, Andrew
- Lim, Emerson
- Manji, Gulam A.
- McKhann, Guy
- McKiernan, James
- Neugut, Alfred
- Olive, Kenneth
- Rosenblat, Todd
- Schwartz, Gary K.
- Shu, Catherine
- Sisti, Michael
- Tergas, Ana
- Vattakalam, Reena
- Welch, Mary
- Wenske, Sven
- Wright, Jason D.
- Hibshoosh, Hanina
- Kalinsky, Kevin
- Aburi, Mahalaxmi
- Sims, Peter A.
- Alvarez, Mariano J.
- Kung, Andrew L.
- Califano, Andrea
- Venue
- Cancer Discovery
- Publisher
- openRxiv
- Published
- 2021-10-03
- Volume
- 13
- Issue
- 6
- Pages
- 1386-1407
- ISSN
- 2159-8274 (ISSN-L)
- PMC
- PMC10239356
- OpenAlex
- W4365997950
- Cited by
- 51
- References
- 85
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 7 · 2023: 10 · 2022: 5
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- CureSearch for Children's Cancer
- Memorial Sloan-Kettering Cancer Center (CA008748, P30 CA008748)
- National Institutes of Health (1s10od021764-01, 1s10od032433-01a1, 1s10od012351-01, CA008748, CA013696)
- Irving Medical Center, Columbia University (P30 CA008748)
- NIH Office of the Director (S10OD021764, S10 OD012351)
- National Cancer Institute (S10OD021764, S10 OD012351, U54CA209997, CA008748, CA013696, OD012351, CA209997, U01CA217858, CA217858, OD021764, P30CA008748, U01CA272610, R35CA197745, P30CA013696)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- precision oncology, patient-derived xenografts, oncotarget, drug response prediction, basket trials, umbrella trials, disease control rate
- MeSH terms
- Antineoplastic Agents, Humans, Medical Oncology, Neoplasms, Precision Medicine, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments. https://app.cochat.ai/papers/10.1101/2021.10.03.462951
- The paper
- Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K. C., Siddiquee, A., You, D., Realubit, R., Karan, C., Ortiz, M. V., Accordino, M., Mistretta, S., Brogan, F., Bruce, J. N., Caescu, C. I., Carvajal, R., Crew, K., . . . Califano, A. (2021). Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments. Cancer Discovery. https://doi.org/10.1101/2021.10.03.462951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.